"Objective: To evaluate the therapeutic intervention with Ivermectin in outpatients with COVID-19 mild disease, to increase medical discharge and prevent the progression to moderate or severe disease.
Methods: Randomized Trial, n= 254. The subjects were divided into experimental (EG: n=110) and control groups (CG: n= 144). The EG received Ivermectin orally 0.6 mg/kg weight in two doses...
Results: A significant reduction in the percentage of participants with symptoms (PPS) was observed in the EG and CG when the clinical evaluation of symptoms was performed from 5th to 9th day (p=0.0005)... A higher proportion of medical discharge was observed in EG (98.2%) vs. CG (86.1%) (p=0.0007). EG showed 8 times more chance of receiving medical discharge than CG (OR 8.71, 95% CI: 1·99 –38.12, p=0.004)...
4. Discussion: ... [I]n our study, outpatients report a significant drop in the percentage of upper airway symptoms in COVID-19 (taste and/or smell disturbance, odynophagia, cough) ... Concomitantly, the results reported here show that the use of Ivermectin produces a decrease in the number of symptoms reported by patients, such as fever and diarrhea, but above all, a significant decrease in taste and smell loss, which is related to the effects of viral load on upper air vials in patients with mild COVID-19."
CC BY 4.0: https://creativecommons.org/licenses/by/4.0/
Copyright (c) 2022 Rossana Elena Chahla; Luis Medina Ruiz; Teresa Mena; Yolanda Brepe; Paola Terranova; Eugenia Silvana Ortega; Guillermo Gabriel Barrenechea; Daniel Gustavo Goroso; María de los Ángeles Peral de Bruno